scholarly journals High-Resolution Physical Map and Transcript Identification of a Prostate Cancer Deletion Interval on 8p22

2000 ◽  
Vol 10 (2) ◽  
pp. 244-257 ◽  
Author(s):  
Z. H. Arbieva
2011 ◽  
pp. P3-111-P3-111
Author(s):  
Nikhil Gupta ◽  
Julie M Wagner ◽  
Neil Resnick ◽  
Subashan Perera ◽  
Megan E Miller ◽  
...  

2001 ◽  
Vol 12 (5) ◽  
pp. 380-386 ◽  
Author(s):  
Annie Robic ◽  
Jin-Tae Jeon ◽  
Virginie Rey ◽  
Valérie Amarger ◽  
Patrick Chardon ◽  
...  

Genomics ◽  
1997 ◽  
Vol 44 (2) ◽  
pp. 214-221 ◽  
Author(s):  
Bora E. Baysal ◽  
Evert M. van Schothorst ◽  
Joan E. Farr ◽  
Michael R. James ◽  
Peter Devilee ◽  
...  

2016 ◽  
Author(s):  
Stefan Kirsch ◽  
Urs Lahrmann ◽  
Miodrag Guzvic ◽  
Zbigniew T. Czyz ◽  
Giancarlo Feliciello ◽  
...  

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Laurence Klotz ◽  
Giovanni Lughezzani ◽  
Davide Maffei ◽  
Andrea Sanchez ◽  
Jose Gregorio Pereira ◽  
...  

Introduction: High-resolution micro-ultrasound has the capability of imaging prostate cancer based on detecting alterations in ductal anatomy, analogous to multiparametric magnetic resonance imaging (mpMRI). This technology has the potential advantages of relatively low cost, simplicity, and accessibility compared to mpMRI. This multicenter, prospective registry aims to compare the sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of mpMRI with high-resolution micro-ultrasound imaging for the detection of clinically significant prostate cancer. Methods: We included 1040 subjects at 11 sites in seven countries who had prior mpMRI and underwent ExactVu micro-ultrasound-guided biopsy. Biopsies were taken from both mpMRI targets (PI-RADS >3 and micro-ultrasound targets (PRIMUS >3). Systematic biopsies (up to 14 cores) were also performed. Various strategies were used for mpMRI target sampling, including cognitive fusion with micro-ultrasound, separate software-fusion systems, and software-fusion using the micro-ultrasound FusionVu system. Clinically significant cancer was those with Gleason grade group ≥2. Results: Overall, 39.5% were positive for clinically significant prostate cancer. Micro-ultrasound and mpMRI sensitivity was 94% vs. 90%, respectively (p=0.03), and NPV was 85% vs. 77%, respectively. Specificities of micro-ultrasound and MRI were both 22%, with similar PPV (44% vs. 43%). This represents the initial experience with the technology at most of the participating sites and, therefore, incorporates a learning curve. Number of cores, diagnostic strategy, blinding to MRI results, and experience varied between sites. Conclusions: In this initial multicenter registry, micro-ultrasound had comparable or higher sensitivity for clinically significant prostate cancer compared to mpMRI, with similar specificity. Micro-ultrasound is a low-cost, single-session option for prostate screening and targeted biopsy. Further larger-scale studies are required for validation of these findings.


1999 ◽  
Vol 5 (S2) ◽  
pp. 392-393
Author(s):  
Joan F. Karr ◽  
Robert P. Apkarian ◽  
John A. Petros

Transfection of mammalian cells can be enhanced by forming complexes between exogenous DNA and cationic peptides which facilitate DNA transport through cell membranes. Although complexes of plasmid DNA and cationic peptides have been characterized by microscopy, little is known about the complexes formed between oligonucleotides (ODN) and cationic peptides or how the ultrastructure of these complexes affects the intracellular delivery via the cell membrane. Because ODN have potential as therapeutic reagents in the treatment of many diseases, there is a need to develop improved methods for effective delivery of these molecules. By analyzing molecular interactions between cationic peptides and ODN and their effects on cell membranes, cell viability, and DNA delivery, improved delivery compounds can be designed. In this paper, we compare the interactions of a 28 base ODN with three cationic peptides: a novel compound, MNLEK (H-Met-(Nle-Lys4)7-Nle-NH2), an established transfection reagent, poly(L-lysine) (∼ 54 kDa), and a recently described cationic peptide which delivers both plasmid DNA and antisense ODN to cells, KALA (WEAKLAKALAKALAKHLAKALAKALKACEA).For high resolution scanning electron microscopy (HRSEM), DU145 human prostate cancer cells were grown overnight on poly-(D-lysine) coated, UV irradiated silicon chips.


Sign in / Sign up

Export Citation Format

Share Document